Intensive medical therapies; and frequent use of atimicrobial drugs capable of seletn a resistant microbial flora. Nosocomial infections due to resistant organisms have been a problem ever since infections due to pen ase-producing Staphylococcus awwrus were noted within a few years of the introduction of penicn. By the 1960s aerobic Gram-negative bacilli had assumed i portance as nosocomial pathogens, and many strains were resistant to available antimicroblals. During the 109s the principal organims causing nosocomial bloodstream infections were cogulase-negative staphylococci, aerobic Gram-negative bacilli, S. aurwus, Candida spp., and Exterococcus spp. Cogulase-negative staphylococci and S. aureus are often me -riant, requiring parenteral use of vancomycin. Prevalence of vancomycin reistance among enterococcal isolates from patients in intensive care units has increased, likely due to increased use of this drug. P -medlat gentamicin ice in up to 50% of enterococcal Isolates, along with enhc penicillin resistance in some strains, leaves few therapeutic options. The emergence of Enterobacteriaceac with chromosomal or plasmid-encoded extended spectrum P-lactamases presents a world-wide problem of resistance to third generation cephalosporins. Control of these infections rests on (a) monitoring infections with such resistant or s in an ongoing fashion, (Ui) prompt Institution of barrier precautions when infected or colonized patients are identfied, and (uia) appropriate use of antimicrlals through implementation of antibiotic control programs.
The -6500 acute-care hospitals in this country represent unique ecological systems and provide the settings for nosocomial (hospital-acquired) infections. The principal components making up these systems are patients, medical-care personnel, equipment and devices employed in the treatment of patients with complicated medical illnesses, and the commensal microbiota ofpatients and the microbial population in the hospital environment. Modern acute-care hospitals are complex institutions consisting of a variety of specialized components: burn services, oncology wards, coronary care units, intensive care units, and transplantation units. Individual units may have particular nosocomial infection problems related to the type of patient being treated or the nature of their underlying illnesses, procedures employed in individual units, and the selection pressure exerted by antimicrobial usage patterns.
Each year there are '-37.7 million admissions to acute-care hospitals in the United States; among these, =2.1 million patients (5.7%) develop nosocomial infections (1) . This is a sizable number and, at first glance, might seem surprising five decades after the beginning of the antibiotic era. A variety of changes account for the current significant role ofnosocomial infections. These alterations include changes in the age of hospitalized patients, the nature oftheir underlying illnesses, the types of surgical and systemic therapy that are now available for treating diseases that were formerly untreatable, and the multitude of antimicrobial drugs currently available and capable of selecting a more resistant microbial flora.
Changing Features of the Population of Hospitalized Patients
The increase in mean life expectancy in the population as a whole is reflected in the increasing age of hospitalized patients. In an acute-care community general hospital in Madison, WI, for example, the percentage of patients 65 years of age or older rose from 13% in 1970-1973 to 24% by 1987 (2) . Similarly, at the Massachusetts General Hospital, the mean age of admissions increased steadily over a 7-year period (1986) (1987) (1988) (1989) (1990) (1991) (1992) ) from 54 to 57 years. Increasing age as a risk factor for nosocomial infections is seen in the analysis of nosocomial infections in elderly patients reported by the National Nosocomial Infections Surveillance (NNIS) system between 1986 and 1990 (3) . Whereas (12) .
The introduction ofpenicillin G into clinical medicine in the mid-1940s was viewed overly optimistically as heralding the elimination of the common bacterial infections, including those acquired within hospitals. Although highly effective initially against S. aureus, a major cause ofhuman infections, subsequent developments belied the initial enthusiasm. Whereas -90% of S. aureus isolates at Boston City Hospital prior to 1946 were susceptible to penicillin, by 1952 =75% of isolates were resistant (13) . In the early 1970s, =75% of S. aureus isolates at the Massachusetts General Hospital were resistant to penicillin. Within a few years, 90%o were penicillin-resistant. Currently, worldwide >95% of S. aureus isolates are resistant to penicillin G as the result of plasmidmediated penicillinase production (14) .
The introduction of penicillin in treatment of human infections was followed in a few years by the introduction of streptomycin, the tetracyclines, erythromycin, and chloramphenicol. As more extensive surgery and cytotoxic drugs were used in treatment and as selection of more antibioticresistant microorganisms developed as a result of broadspectrum antibiotic usage, the frequency ofhospital-acquired infections increased. At Boston City Hospital, the frequency of hospital-acquired bacteremias and fungemias steadily increased (with few fluctuations) between 1935 and 1972 from a rate of 3.7 per 1000 hospital admissions to a rate of 14.7 per 1000 admissions (15) . Most (Fig. 1) . By the early 1970s, -55% of blood isolates were Gram-negative aerobic bacilli; -40% were Gram-positive aerobic cocci, and the remainder were Candida or Torulopsis spp. Between 1941 and 1972, the percentage of S. pneumoniae among bacteremic Grampositive coccal strains declined from 15 to 4% and that of enterococci increased from 3 to l9o. Among Gram-negative bacilli, the principal changes observed between 1941 and 1972 were a decline in frequency for Escherichia coli from 66 to 27% and an increase in Klebsiella-Enterobacter from 0 to 39%6 (15, 16) . sent -8% of all hospital-acquired infections in the United States (3, 17) . The frequency of bloodstream infection varies with the category of hospital (18) . The rate for small nonteaching hospitals is the lowest (1.3 per 1000 discharges) followed by that for large nonteaching hospitals (2.5 per 1000 discharges). The highest rate (6.5 per 1000 discharges) occurs in large teaching hospitals, followed by the rate ( Aerobic Gram-negative bacilli, which had achieved prominence in the previous two decades, showed no change in frequency in large teaching hospitals. The spectrum of microbial pathogens involved overall in nosocomial infections differs somewhat from that causing only bacteremia/fungemia (19 aureus; bloodstream infection, CNS. Over the past decade there has been a decline in the frequency of E. coli infections and increases in infections due to CNS (from 4% of total infections to 9%) and Candida albicans (from 2 to 5%). In the past decade the trend has been away from antimicrobialsusceptible species to more resistant pathogens. Even among susceptible species, there has been a shift from readily susceptible to antibiotic-resistant strains.
Overall datafor a large number ofhospitals are very helpful in identifying major trends. However, they may tend to obscure outbreaks that occur in individual hospitals and important shifts that occur in antimicrobial susceptibilities of pathogens that present problems in individual intensive-care units. For example, among 392 nosocomial infections occurring among 920 neutropenic cancer patients in a cancer unit, Candida spp. (18%) was the most common pathogen followed closely in frequency by CNS (17%) (10) . In addition to common microorganisms seen in the multihospital NNIS survey, less frequently observed pathogens such as Clostridium spp., Corynebacterium spp., Aspergillus spp., and herpes viruses may account for 20%o of the total pathogen group.
Problems of Antmhicrobial Resbtance In Selected Nosocomi Pathogens S. awreus. Methicillin-resistant S. aureus (MRSA) was first described in 1961 in England and over the next decade became an important nosocomial pathogen in parts of Europe (20) . MRSA is resistant to all penicillins, including semisynthetic penicillinase-resistant congeners, penems, and carbapenems. The basis for this resistance is the mecA gene that codes for a new penicillin-binding protein (PBP; PBP2a) with a reduced affinity for all 3-lactam antibiotics (21) . The mecA gene is chromosomal in location and not subject to dissemination among staphylococcal strains via plasmid spread. However, resistance to other antibiotics such as streptomycin, tetracyclines, trimethoprim, and erythromycin can be spread widely via plasmids and by transposition in many MRSA (21) . In the early 1970s, the prevalence of MRSA temporarily receded only to reemerge in the past one and a half decades as a cause of nosocomial outbreaks of infections in Europe, Africa, Asia, Australia, and the United States (22) . The prevalence of MRSA among S. aureus isolates reveals marked differences between countries: 0.1% in Denmark in 1988,4% in Germany in 1989,26% in France in 1989, and 15% in the United States in 1987-88. However, these represent mean prevalence rates for many hospitals. Although the average prevalence rate of MRSA among 24 hospitals in Italy was 26% in 1986, the survey included hospitals with prevalence rates that varied from 6 to 44% (22) . In the NNIS data from U.S. hospitals evaluated over a 17-year period (1975-1991) , the percentage of MRSA increased from 2.4% in 1975 to 29%6 (23 (27) . In Denmark in the 1950s, the S. aureus strains isolated were frequently of the 52/52A/80/81 complex, but these were replaced increasingly in the early 1960s by tetracycline-resistant strains of the 83A complex; 70% of these were multiresistant (45% methicillin resistant The increasing role of CNS as a pathogen in infections involving prosthetic devices (artificial heart valves, cardiac pacemaker leads, joint replacements, nervous system ventricular shunts, peritoneal dialysis catheters, and polyethylene intravenous catheters) has occurred contemporaneously with development of increasing methicillin-resistance. Staphylococcus epidermidis, a common commensal on human skin, is frequently the species infecting foreign body implants or indwelling venous catheters, but other CNS species may also be involved. Binding of such organisms to foreign-body surfaces and their intercell adherence is enhanced by a biofilm matrix (extracellular "slime layer" consisting of exopolysaccharides) they produce. Colonization within a biofilm appears to protect S. epidermidis cells against opsonization and phagocytosis by polymorphonuclear leukocytes, and it may afford protection against the bactericidal action of antibiotics by acting as a barrier to the latter's penetration (30) .
CNS (and S. aureus) have developed resistance mechanisms for evading the inhibitory action of many antimicrobials previously useful in treating infections due to these microorganisms (14) . They have acquired plasmid genes encoding f-lactamase production that render them (>90%) resistant to penicillin G. MRSA are resistant to methicillin and other penicillinase-resistant penicillins, cephalosporins, carbapenems, and penems by virtue of a chromosomal gene (mecA) that encodes a new PBP (PB2a) with reduced affinity for all 1-lactam antibiotics. Fluoroquinolone resistance in clinical isolates of S. aureus is associated with mutations in the A subunit of the DNA gyrase (31) . A second form of resistance to fluoroquinolones in S. aureus is due to a mutation (norA) in the chromosomal gene that codes for a membrane transporter effecting fluoroquinolone efflux driven by the proton gradient across the cell membrane (32) . Rifampin resistance in S. aureus is encoded on the chromosomal gene for the DNA-dependent RNA polymerase and involves an alteration in the B subunit to which rifampin binds. Rifampin is not used alone to treat staphylococcal infections because of rapid emergence of resistance.
Staphylococcal infections are not ordinarily treated with aminoglycosides, but a drug in this class is sometimes combined with a penicillinase-resistant penicillin in the treatment of life-threatening infections. Plasmid-mediated aminoglycoside-modifying enzymes (phosphotransferase, adenylylating enzyme, and acetyltransferase) alter the conformation of these antibiotics and interfere with binding of the aminoglycoside to the 30S ribosomal subunit, a necessary step in aminoglycoside action (formation of an unstable initiation complex, thus blocking translation and exerting a bactericidal effect).
Resistance in staphylococci to tetracyclines is encoded on plasmids or transposons that cause synthesis of a new membrane protein that decreases accumulation of tetracycline by causing active efflux of the drug (33) . Resistance to macrolides (erythromycin and clindamycin) is primarily plasmid-mediated and inducible, involving methylation of an adenine in the 23S ribosomal RNA of the 50S ribosomal subunit. This results in decreased binding of the macrolides to their usual targets on the ribosome (34) . Trimethoprim resistance is common (=40%) among CNS and is somewhat more frequent than among S. aureus isolates (35) . The same genetic resistance determinant is found on conjugative multiresistant plasmids and on the chromosome in both species. The principal mechanism of resistance has been production of new plasmid-mediated dihydrofolate reductases that are trimethoprim-resistant (36 Enterococci are intrinsically more resistant in vitro to penicillin (MIC, 2.5-5 pg/ml) than are other streptococci (MIC, Q.02-0.08 pg/ml). Since the reports ofHunter (38) in 1947 and of Jawetz et al. (39) in 1950, the capacity of penicillin and an aminoglycoside to act synergistically against enterococci has been known. The bactericidal action of this combination is due to limited penicillin inhibition of bacterial cell wall synthesis that permits enhanced uptake of aminoglycoside, the latter then acting lethally on its ribosomal target (40) . Treatment of serious enterococcal infections has involved the use of combined penicillin-aminoglycoside therapy since the 1950s. Originally, the aminoglycoside was streptomycin. By the early 1970s, 25-50% of clinical isolates showed high-level (>2000 pg/ml) resistance to streptomycin and kanamycin. Accordingly, gentamicin was substituted for streptomycin. The penicillin and gentamicin combination proved to be synergistic in vitro against all enterococci tested during the 1970s and provided effective therapy. However, in 1979 the first enterococcus isolate with high-level (>2000 pg/ml) resistance to gentamicin was identified in Paris (41) . Subse- quently, enterococci with high-level gentamicin resistance and resistance to penicillin-gentamicin synergy have been observed worldwide (42) . By the early 1990s, in some centers, >50%o of enterococcal isolates showed resistance to penicillin-gentamicin synergy. Among Enterococcus faecium isolates, which prior to 1987 had been uniformly susceptible to gentamicin at 2000 pg/ml, in some hospitals as many as 70%o of isolates showed high-level resistance to gentamicin.
High-level resistance to streptomycin is due either to plasmid-mediated (adenylyltransferase) modification of the drug or, occasionally, can be due to a chromosomal mutation that alters ribosomal affinity for streptomycin (42) . Highlevel gentamicin resistance is based on enzymatic modification ofthe aminoglycoside by a plasmid-encoded bifunctional enzyme with both 2"-phosphotransferase and 6'-acetyltransferase activities (43) . Aminoglycoside modification by this bifunctional enzyme prevents penicillin (or vancomycin) synergy with all available aminoglycosides except streptomycin. Fortunately, up to 46% of high-level gentamicinresistant Enterococcus faecalis isolates are still susceptible to streptomycin. While all enterococci exhibit low-level intrinsic resistance to aminoglycosides, the MICs of certain aminoglycosides, (tobramycin, kanamycin, netilmicin, and sisomicin) are higher in E. faecium than E. faecalis. This relative resistance is based on a chromosomally mediated 6'-acetyltransferase and is of sufficient degree to prevent synergy with cell-wall-active antimicrobial agents (42) .
To add to the problems produced by high-level gentamicin resistance in treatment of serious enterococcal infections, major resistance to penicillin has emerged. Although a variety of less frequently isolated Enterococcus species (E. gallinarum, E. casseliflavus, E. durans, E. avium, and E. raffinosus) have occasionally been responsible for infections, most clinical isolates have been E. faecalis (85-90%o) and E. faecium (5-10%1). Penicillin resistance in enterococci has been of two types: (i) higher levels of intrinsic resistance to penicillin and other 3-lactams, particularly in E.faecium, and associated with production of greater amounts of a lowaffinity PBP (PBP5) (44); (ii) ,B-lactamase production by enterococci (Bla+) carrying plasmids and exhibiting highlevel gentamicin resistance (HLGR) as well. A large outbreak of infections has been caused by a clone identified in the mid-Atlantic area (45) . Such a strain (Bla+ HLGR), once ensconced in a hospital, is difficult to eradicate, reminiscent of the problem with MRSA. In one outbreak, the 3-lactamase and high-level gentamicin-resistance genes were chromosomal in location, probably on a conjugative transposon (46) . Although penicillin resistance due to 3-lactamase production is as yet uncommon in enterococci, it presents a major threat, particularly if conjugative spread occurs.
Vancomycin resistance among clinical enterococcal isolates, particularly E. faecium strains highly resistant to penicillin because of their low-affinity PBPs, was first recognized in England and France in the late 1980s, -30 years after the glycopeptide had been introduced in clinical use. Subsequent nosocomial outbreaks due to vancomycinresistant E. faecium have occurred in several hospitals in the United States, including a cardiothoracic intensive care unit in one (47) and a medical-surgical intensive care unit in another (48) . In the latter, nondisposable handles of electronic rectal thermometers were the means of spread of enterococci. In outbreaks some patients have developed serious infections such as bacteremia, peritonitis, and pneumonia. In a survey of 10,961 nosocomial enterococcal strains collected between 1989 and 1993 in the NNIS hospital system, 2.5% were found to be vancomycin-resistant (49 13.6% in 1993. Vancomycin resistance in enterococci consists of several different phenotypes (50) . The VanA phenotype consists of inducible high-level resistance to both vancomycin and another glycopeptide, teicoplanin, that is mediated by a transposable element (TnJS46) on a conjugative plasmid in E.
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Colloquium Paper: Swartz faecium, E. faecalis, and E. avium. The expression of the VanB phenotype is inducible in E. faecium and E. faecalis and transferable by conjugation, but the location of the resistance genes is unknown and the resistance is to vancomycin and not to teicoplanin. The VanC phenotype is probably mediated by a chromosomal gene, present in E. gallinarum and E. casseliflavus, constitutive, and confers lowlevel resistance only to vancomycin.
Normal peptidoglycan synthesis involves the sequential action of D-Ala:D-Ala ligase and D-Ala-D-Ala adding enzyme to ultimately produce D-Ala-D-Ala termini on the pentapeptide side chains of the nascent bacterial cell wall (50, 51) . The amide of the terminal D-Ala-D-Ala of vancomycin-susceptible bacteria appears to form a crucial hydrogen bond with a carbonyl group on the vancomycin skeleton (Fig. 3) (51) . This NH group appears to be essential for vancomycin binding to the cell wall and its inhibition oftransglycosylation and transpeptidation of growing peptidoglycan strands.
Vancomycin-resistant bacteria, such as enterococci with the VanA phenotype, have acquired a transposable element, TnJS46, encoding nine genes, on a plasmid. The resistance gene products include a transmembrane sensor protein (VanS) that resembles eukaryotic transmembrane receptors. The latter senses the presence of vancomycin and transduces that information to a response regulator protein (VanR) that is a transcriptional activator of vanH and vanA genes (51) . The latter two genes are critical in the subsequent expression of drug resistance (Fig. 3) hemolyticus have shown resistance to vancomycin (53) .
Inherent resistance to vancomycin is a feature of Leuconostoc spp., Pediococcus spp., and Lactobacillus spp., all three rarely causing human infections.
A threat exists of further dissemination of vancomycin resistance to other species via transposition of TnlS46 into broad-host-range plasmids. Barriers do not exist to heterospecific expression of enterococcal resistance genes in Listeria monocytogenes, Bacillus spp., and Streptococcus spp. (50) . Transfer ofvancomycin resistance from E.faecalis to S. aureus via conjugation in the laboratory raises the frightening possibility of the emergence of glycopeptide resistance in MRSA (54).
Resistance to Third-Generation Cephalosporins Among Gram-Negative Aerobic Bacilli
Resistance of Gram-negative pathogens to f-lactam antibiotics is mediated by any one ofthree mechanisms (production of 3lactamases, reduced permeation of the drug, or alteration of the target site, i.e., PBP) or by several acting in concert. In the mid-1980s, it was noted that resistance was developing among Gram-negative bacilli possessing inducible chromosomal cephalosporinases (e.g., Enterobacter cloacae, Proteus spp., Serratia spp., Citrobacterfreundii) when certain of the newer cephalosporins and cephamycins were used in therapy (55) . Spontaneous mutation of such organisms to a stably derepressed (induced) state resulted in persistence in these mutants of high levels of /-lactamase even without the presence of an inducer. Such resistance is not transmissible but has been responsible for many instances of therapeutic failure, relapse, or nosocomial spread of such infections (56) CoUoquium Paper: Swartz Further problems in the treatment of infections due to Gram-negative bacilli became evident in the mid 1980s in France and Germany when Klebsiella isolates with plasmidmediated resistance to broad-spectrum cephalosporins (cefotaxime, ceftriaxone, and ceftazidime) and aztreonam appeared (57) . Such resistance soon became evident worldwide (58) . The basis of such resistance is the emergence of new extended-spectrum P-lactamases, observed first in Klebsiella pneumoniae and subsequently in E. coli, C.freundii, Serratia marcescens, and Enterobacter cloacae. These new resistances are mediated by plasmids encoding TEM-1-, TEM-2-, and SHV-1-related (mutated) (3-lactamases. These new extended-spectrum (3-lactamases differ from the original plasmid-encoded TEM-1 (-lactamase (mediating ampicillin resistance in Gram-negative enteric bacteria) and plasmidencloded SHV-1 f-lactamase in Klebsiella, by 1-4 amino acids; and, thus, they are designated (TEM-4, etc.) to indicate this relatedness. The prevalence of extendedspectrum 3-lactamases in Enterobacteriaceae has risen disturbingly over the past 7 or 8 years. For example, among isolates of K. pneumoniae from patients in 20 French hospitals, the prevalence of such resistance increased from <1% in 1985 to 11% in 1988 (56) . In 1988-1989 in one hospital in Athens, Greece, 24% of K. pneumoniae and 4% of E. coli isolates possessed extended-spectrum (3-lactamases. Enterobacteriaceae producing extended-spectrum P-lactamases have been responsible for a number of nosocomial outbreaks, usually originating in an intensive care unit and then spreading elsewhere (56) . Such dissemination of drug resistance can involve spread of a particular strain of bacteria, horizontal interspecies spread of a resistance plasmid, or spread of resistance genes. Either extensive use of an extendedspectrum cephalosporin in a hospital unit or prior use in a particular patient has usually been associated with such outbreaks. Since K. pneumoniae containing extendedspectrum (-lactamases also often carry genes for amikacin resistance on the same plasmids, high-level use of the aminoglycoside may serve to select for resistant strains.
The potential for selection of increasingly resistant Gramnegative bacillary pathogens in a hospital can be seen in the sequence of events in one U.S. hospital over several years. In 1988-1989, a major outbreak of infections due to Acinetobacter occurred, requiring extensive use of ceftazidime, and to a lesser degree, imipenem, to which the infecting strain was susceptible. Late in 1988 an outbreak of ceftazidimeresistant K. pneumoniae infections began and 155 patients were infected or colonized during a 2-year period (59) . Predisposing factors included >2 weeks of hospitalization and >7 days of antibiotic administration. Prior to isolation of the ceftazidime-resistant K. pneumoniae on average almost five antibiotics per patient had been administered. These isolates were resistant to aminoglycosides and to the bactericidal action of all third generation cephalosporins, moxalactam, and cephamycins and were susceptible only to imipenem. The strains examined contained several plasmids and produced 3-lactamases with enzymatic characteristics suggesting TEM-10 or TEM-26. The outbreak was finally controlled with a combination of antibiotic (ceftazidime) restriction and barrier precautions for all infected or colonized patients.
The use of imipenem to treat infected patients in the aforementioned hospital outbreak increased 3-to 4-fold. Subsequently, an outbreak of nosocomial infections (pulmonary and bacteremic) occurred in the surgical intensive care unit of the same hospital due to a strain of multiresistant Acinetobacter calcoaceticus (60) . The organism was resistant to all antimicrobials ordinarily employed against Gram- negative aerobic bacilli: aminoglycosides (including amikacin); ampicillin; antipseudomonal penicillins; first-, second-, and third-generation cephalosporins; cephamycins; fluoroquinolones; aztreonam; imipenem; chloramphenicol; etc. The only antimicrobials to which the A. calcoaceticus isolates were susceptible were ampicillin-sulbactam (sulbactam responsible for the bactericidal effect ofthe combination) and polymyxin.
The above-described sequential outbreaks of nosocomial infections due to increasingly resistant organisms emphasizes the potentially great selective power of extensive antimicrobial use in a given institution, particularly in intensive care units, in favoring emergence of multiresistant pathogens.
Control Of Nosocomial Infections Due to Reistactsacteria
In the past the rate of introduction of new antimicrobial drugs has been sufficient to counter those infections caused by organisms resistant to available drugs. Although there are >155 antibiotics (14) , the rate of introduction of genuinely new drugs with different modes of action or genuinely different spectra of activity into clinical usage has slackened. Therapeutic options for nosocomial infections are increasingly limited because of antimicrobial resistance.
Control of this group of infections merits consideration of changes in some current practices. (i) Monitoring of nosocomialpathogens and their resistance patterns in acute-care hospitals. Although it is common practice for hospital microbiology laboratories to collect data on the antimicrobial susceptibilities of major pathogens and to provide summary information to physicians, such data commonly is tabulated for the recent year's experience, encompasses results from all parts of the hospital (including ambulatory services), and is provided to the physicians months later. This information is helpful for guidance in antimicrobial selection when a given pathogen has been identified or is suspected but its antimicrobial susceptibilities have not yet been determined. However, such information is less helpful in identifying early phases of nosocomial outbreaks in specialized units, since the data may become available late in the outbreak and may be obscured by collating susceptibilities from all parts of a hospital. In addition, data is not readily available in the form of antimicrobial-resistance patterns. Early detection of outbreaks of nosocomial infection may be improved by ongoing monitoing ofpathogens isolated and their resistance patterns in selected intensive care units on a monthly basis. (ii) Prompt institution of barrier precautions. Early identification of the new multiresistant pathogen serves to alert intensive care unit personnel to the problem and to institute isolation precautions before the strain is widely transmitted within the unit and elsewhere in the hospital. Once the number of infected and colonized patients increases containment becomes much more problematic. (iii) Judicious use of antimicrobial agents. The use ofantimicrobials by physicians in hospitals (and elsewhere) requires acute awareness of the increasing problems with resistant organisms. Thus, unnecessary use of an antimicrobial drug has public health implications. Such use may serve to select for resistant organisms that may be carried to other more vulnerable patients and produce serious difficult-to-treat infections. Antibiotic control programs can be an effective means to prevent inappropriate use of antimicrobials in hospitals. Newer antimicrobials should be included in such programs to delay the emergence of resistant strains by limiting unnecessary use of such drugs. Indeed, consideration might be given in some instances to cycling the use ofcertain antimicrobials in selected intensive care units.
